Tag: NASD:NMTR

At last check in after-hours trading, shares of clinical-stage company focused on rare and unmet needs in gastroenterology  9 Meters Biopharma Inc. (NMTR) were down -3.23% at $1.20. Last session, 9 Meters closed at $1.24, up 20.39% or $0.21. During regular trading, the share price of NMTR fluctuated between $1.03 and $1.42.

There were 43.89 million shares of NMTR stock exchanged, more than the daily volume of 5.11 million for the past 50 days and higher than the volume for the year to date. NMTR stock has fallen 101.36% in the past 12 months and has risen 12.73% in the last week. Over the past three months, NMTR shares have increased by 4.20%, and the stock has dropped by -9.49% during the last six months.

NMTR stock rose during the regular session on news that it will participate in a biotech conference but has lost ground after hours.

NMTR will participate in which event?

9 Meters Biopharma is a gastroenterology company focused on rare and unmet needs. NMTR is developing vurolenatide, an orphan disease medicine, in a Phase 2 clinical trial for short bowel syndrome (SBS). Larazotide, another tight junction regulator, is also being evaluated by NMTR to improve symptoms of celiac disease.

NMTR CEO John Temperato will participate in a virtual fireside chat at a health event, announced 9 Meters Biopharma.

The NMTR CEO will take part in the William Blair Biotech Focus Conference on July 14-15, 2021. Investors are invited to join NMTR’s webcast live. John Temperato, Chief Executive Officer of 9 Meters Biopharma, will present at the William Blair Biotech Focus Conference on Thursday, July 15, 2021 at 12:00 to 2:45 p.m. Eastern Time.

The presentation will be webcast live and may be accessed on the Investors page of the company’s website at https://wsw.com/webcast/blair59/nmtr/1964248, where a replay of the presentation will also be available for a 30-day period.

Moreover, at the conclusion of the annual Russell US Index reconstitution, 9 Meters Biopharma was added to the Russell 3000 Index, a broad-market index, and the Russell 2000 Index, a small-cap index. As of the opening of the US equity markets on Monday June 28, 2021, these updated Indexes are in effect.

The Russell indexes represent the 4,000 biggest US stocks based on their total market capitalization as of May 7, 2021. FTSE Russell determines membership for its Russell indexes primarily through objective rankings and criteria that are associated with market capitalization.

What its addition to Russell means for NMTR?

NMTR’s perseverance and accomplishments, including adding 9 Meters to the Russell Indexes, are indicative of its efforts to become a treatment leader in rare and unmet gastrointestinal disorders. By including 9 Meters Biopharma (NMTR) in the Russell Indexes, the company will raise its visibility when it is nearing several key milestones.

In premarket trading on Tuesday, 9 Meters Biopharma Inc. (NMTR) shares were up 3.51% at $1.18. At the end of last trading session, 9 Meters stock closed at $1.14, down 5.0%. A trading volume of 13.59 million shares was recorded by NMTR stock in the last trading session, much higher than the average daily volume of 4.2 million shares for the previous 50 days.

In the past five days, NMTR’s stock has retreated -18.57%. Over the past month, the stock has fallen -10.24%. In the last three months, the price of NMTR stock has dropped by 13.64%, but has gained 32.71 percent so far this year. After joining the Russell index last session, NMTR stock has been rising.

Has Russell index’s inclusion impacted NMTR?

9 Meters Biopharma focuses on rare and unmet gastroenterology needs. NMTR will enroll vurolenatide, a proprietary long-acting GLP-1 agonist, in a Phase 2 clinical trial for short bowel syndrome (SBS). SBS is NMTR’s focal point due to its rarity and orphan status, as well as its Phase 3 tight junction regulator, which is being evaluated for signs and symptoms of non-responsive celiac disease.

At the conclusion of the Russell US Indexes annual reconstitution, 9 Meters joined the Russell 3000 Index and the Russell 2000 Index for broad-market and small-cap companies, respectively.

• On June 28, 2021, after the opening of the US equities markets, these updated indices took effect.
• The Russell indexes are reconstituted annually and contain 4,000 of the largest US stocks as of May 7, 2021, ranked by market capitalization.
• NMTR’s achievement of adding 9 Meters to this Russell Index is an indication of both the perseverance and achievement of the team as it continues to work towards becoming the treatment leader for rare, unmet gastroenterology disorders.
• As NMTR gains momentum towards several milestones, inclusion in the Russell Indexes will increase its visibility among the international investment community.

NMTR stepping towards its goals:

9 Meters Biopharma (NMTR) recently initiated its Phase 2 trial of vurolenatide, a proprietary long-acting glucagon-like peptide-1 (GLP-1) agonist in adults with SBS. 9 Meters Biopharma is launching a Phase 2 trial of vurolenatide, which represents an important accomplishment for not only the company, but also for patients and families suffering from the devastating effects of SBS, including chronic diarrhea. As a result, NMTR may be a step closer to having longer-acting, more rapid-onset therapy and with a lower safety profile than any currently available therapy, potentially for the benefit of patients.